Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.6%

159 terminated/withdrawn out of 1165 trials

Success Rate

80.6%

-6.0% vs industry average

Late-Stage Pipeline

2%

25 trials in Phase 3/4

Results Transparency

66%

435 of 661 completed trials have results

Key Signals

141 recruiting435 with results123 terminated36 withdrawn

Enrollment Performance

Analytics

Phase 2
459(42.9%)
N/A
311(29.1%)
Phase 1
258(24.1%)
Phase 3
21(2.0%)
Early Phase 1
17(1.6%)
Phase 4
4(0.4%)
1070Total
Phase 2(459)
N/A(311)
Phase 1(258)
Phase 3(21)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1165)

Showing 20 of 1165 trials
NCT02326974Phase 2Active Not Recruiting

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Role: lead

NCT07101458Not ApplicableActive Not Recruiting

The Eswatini PRISM Study on Adolescents Living With HIV

Role: collaborator

NCT06000787Not ApplicableRecruiting

MCT for the Harvard/UCSF ROBIN Center

Role: collaborator

NCT06565052Not ApplicableRecruiting

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

Role: lead

NCT03749421Completed

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

Role: lead

NCT07847957Phase 1Not Yet Recruiting

Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

Role: lead

NCT03391362Not ApplicableActive Not Recruiting

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Role: collaborator

NCT03679650Phase 1Active Not Recruiting

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

Role: collaborator

NCT03059485Phase 2Active Not Recruiting

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Role: collaborator

NCT04720209Not ApplicableActive Not Recruiting

Taking AIM at Breast Cancer

Role: lead

NCT03075072Not ApplicableActive Not Recruiting

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Role: collaborator

NCT03668340Phase 2Active Not Recruiting

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Role: lead

NCT06084234Phase 4Recruiting

National Liver Cancer Screening Trial

Role: collaborator

NCT07729150Not ApplicableRecruiting

Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

Role: lead

NCT04417062Phase 2Active Not Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Role: lead

NCT02974647Phase 2Recruiting

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Role: collaborator

NCT03716180Phase 1Active Not Recruiting

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Role: lead

NCT07838389Phase 1Not Yet Recruiting

Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)

Role: collaborator

NCT04584255Phase 2Active Not Recruiting

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Role: lead

NCT03668223Not ApplicableCompleted

The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer

Role: lead